HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells

Retrovirology

Volumn 8, Issue , 2011, Pages

  Gibellini, Davide ^a   Alviano, Francesco ^a   Miserocchi, Anna ^a   Tazzari, Pier L ^b   Ricci, Francesca ^b   Clò, Alberto ^a   Morini, Silvia ^a   Borderi, Marco ^a   Viale, Pierluigi ^a   Pasquinelli, Gianandrea ^a   Pagliaro, Pasqualepaolo ^b   Bagnara, Gian P ^a   Re, Maria C ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Apoptosis; Cell differentiaton; Gp120; HIV 1; Mesenchymal stem cells

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD146 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; GLYCOPROTEIN GP 120; HERMES ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THY 1 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VIRUS DNA; VON WILLEBRAND FACTOR; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADIPOGENESIS; ADULT; APOPTOSIS; ARTICLE; BLOOD VESSEL WALL; CD34 SELECTION; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MESENCHYMAL STEM CELL; PERIPHERAL VASCULAR SYSTEM; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS STRAIN; BLOOD VESSEL; CELL CULTURE; CYTOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; APOPTOSIS; BLOOD VESSELS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; MESENCHYMAL STEM CELLS; VIRUS INTEGRATION; VIRUS INTERNALIZATION;

EID: 80053103000     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-40     Document Type: Article

References (94)

1. Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009, 23:147-160. 10.1097/QAD.0b013e3283217f9f, 19098484.
2. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003, 9:839-843. 10.1038/nm0703-839, 12835701.
3. Mattison MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death Differ 2005, 12:893-904.
4. Borderi M, Gibellini D, Vescini F, Biagetti C, De Crignis E, Re MC. Metabolic bone disease in HIV infection. AIDS 2009, 23:1297-1310. 10.1097/QAD.0b013e32832ce85a, 19550284.
5. Haggerty C, Pitt E, Siliciano R. The latent reservoir for HIV in resting cells and other viral reservoirs during chronic infection: insight from treatment and treatment-interruption trials. Curr Opin HIV AIDS 2006, 1:62-68. 10.1097/01.COH.0000191897.78309.70, 19372786.
6. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human immunodeficiency-virus-positive patients. Coron Artery Dis 2000, 11:41-46. 10.1097/00019501-200002000-00008, 10715805.
7. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, Maa JF, Hodder S. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003, 33:506-512. 10.1097/00126334-200308010-00012, 12869840.
8. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710. 10.1056/NEJMoa022048, 12594314.
9. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular diseases and endothelial dysfunction. World J Surg 2007, 31:632-643. 10.1007/s00268-006-0730-0, 17372667.
10. Crowe SM, Westhorpe CLV, Mukhamedova N, Jawororowski A, Sviridov D, Burkinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010, 87:589-598. 10.1189/jlb.0809580, 3085483, 19952353.
11. Joshi VV, Pawel B, Connor E, Sharer L, Oleske JM, Morrison S, Marin-Garcia J. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987, 7:261-275. 10.3109/15513818709177129, 3684808.
12. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993, 144:225-231.
13. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, von Kegler S, Ruhkamp D, Steinmetz H, Sitzer M. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008, 196:720-726. 10.1016/j.atherosclerosis.2006.12.022, 17275008.
14. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, ien PC, Shlipak MG, Sidney S, Polak JF, O'Leary D, Bacchetti P, Kronmal RA. Preclinical atherosclerosis due to HIV infection: carotid intimamedial thickness measurements from the FRAM study. AIDS 2009, 23:1841-1849. 10.1097/QAD.0b013e32832d3b85, 19455012.
15. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23:1059-1067. 10.1097/QAD.0b013e32832b514b, 2691772, 19390417.
16. Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003, 17:S70-S76.
17. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008, 118:e29-e35. 10.1161/CIRCULATIONAHA.107.189624, 18566319.
18. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health. J Am Coll Cardiol 2009, 53:2315-2323. 10.1016/j.jacc.2009.02.057, 19539140.
19. Hansson GK. Inflammation, Atherosclerosis and coronary artery disease. N Eng J Med 2005, 352:1685-1695.
20. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009, 27:165-197. 10.1146/annurev.immunol.021908.132620, 2734407, 19302038.
21. Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990, 76:2303-2310.
22. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992, 66:7159-7167. 240407, 1279199.
23. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassare F, Dragonetti E, Quinto I, Venuta S. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994, 179:961-971. 10.1084/jem.179.3.961, 2191426, 8113688.
24. Barqasho B, Nowak P, Tjernlund A, Kinloch S, Goh LE, Lampe F, Fisher M, Andersson J, Sönnerborg A, . QUEST study group Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. HIV Med 2009, 10:94-102. 10.1111/j.1468-1293.2008.00657.x, 19200172, QUEST study group.
25. Birdsall HH, Porter WJ, Green DM, Rubio J, Trial J, Rossen RD. Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes. J Immunol 2004, 173:2746-2754.
26. Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006, 80:11486-11497. 10.1128/JVI.00324-06, 1642603, 17005663.
27. Zucker-Franklin D, Grusky G, Marcus A. Transformation of monocytes into "fat" cells. Lab Invest 1978, 38:620-628.
28. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Svirdov D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006, 4:e365. 10.1371/journal.pbio.0040365, 1629034, 17076584.
29. Bukrinsky M, Sviridov D. HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis. PLoS Med 2007, 4:e43. 10.1371/journal.pmed.0040043, 1796648, 17411317.
30. Huang MB, Khan M, Garcia-Barrio M, Powell M, Bond VC. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr 2001, 27:213-221.
31. Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 2000, 96:1438-1442.
32. Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001, 167:2766-2771.
33. Asahara T, Murohara T, Sullivan A, Silver M, Van der Zee R, Li T, Witzenbichler B, Schatterman G, Isler JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967. 10.1126/science.275.5302.964, 9020076.
34. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 2002, 11:171-178. 10.1089/152581602753658385, 11983091.
35. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004, 287:C572-C579. 10.1152/ajpcell.00330.2003, 15308462.
36. Ergun S, Hohn HP, Kilic N, Singer BB, Tilki D. Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 2008, 4:169-177. 10.1007/s12015-008-9028-y, 18607782.
37. Klein D, Hohn HP, Kleff V, Tilkl D, Ergun S. Vascular wall-resident stem cells. Histol Histopathol 2010, 25:681-689.
38. Pasquinelli G, Pacilli A, Alviano F, Foroni L, Ricci F, Valente S, Orrico C, Lanzoni G, Buzzi M, Tazzari L, Pagliaro PP, Stella A, Bagnara GP. Multidistrict human mesenchymal vascular cells: pluripotency and stemness characteristics. Cytotherapy 2010, 12:275-287. 10.3109/14653241003596679, 20230218.
39. Scadden DT, Zeira M, Woon A, Wang Z, Schieve L, Ikeuchi K, Lim B, Groopman JE. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1990, 76:317-322.
40. Wang L, Mondal D, La Russa VF, Agrawal KC. Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type 1 tat protein and inflammatory cytokines. AIDS Res Hum Retroviruses 2002, 18:917-931. 10.1089/088922202760265597, 12230935.
41. Cotter EJ, Ip HSM, Powderly WG, Doran PP. Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskeletal Disorders 2008, 9:33. 10.1186/1471-2474-9-33, 2330047, 18366626.
42. Cotter EJ, Chew N, Powderly WG, Doran PP. HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex-vivo. AIDS Res Hum Retrov 2011, 27:187-199.
43. Canque B, Marandin A, Rosenzwajg M, Louache F, Vainchenker W, Gluckman JC. Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV). Virology 1995, 208:779-783. 10.1006/viro.1995.1211, 7747451.
44. Pasquinelli G, Tazzari PL, Vaselli C, Foroni L, Buzzi M, Storci G, Alvaino F, Ricci F, Bonafè M, Orrico C, Bagnara GP, Stella A, Conte R. Thoracic aortas from multiorgan donors are suitable for obtaining resident angiogenic mesenchymal stromal cells. Stem Cells 2007, 25:1627-1634. 10.1634/stemcells.2006-0731, 17446560.
45. Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, Lanzoni G, Cantoni S, Cavallini C, Bianchi F, Tazzari PL, Pasquinelli G, Foroni L, Ventura C, Grossi A, Bagnara GP. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 2007, 7:11. 10.1186/1471-213X-7-11, 1810523, 17313666.
46. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehringer G, Bornhauser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384. 10.1634/stemcells.22-3-377, 15153614.
47. Chelucci C, Federico M, Guerriero R, Mattia G, Casella I, Pelosi E, Testa U, Mariani G, Hassan HJ, Peschle C. Productive human immunodeficiency virus-1 infection of purified megakaryocytic progenitors/precursors and maturing megakaryocytes. Blood 1998, 91:1225-1234.
48. Guo L, Heinzinger NK, Stevenson M, Schopfer LM, Salhany JM. Inhibition of gp120-CD4 interaction and human immunodeficiency virus type 1 infection in vitro by pyridoxal 5'-phosphate. Antimicrob Agents Chemother 1994, 38:2483-2487. 284769, 7530934.
49. Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, Giardino R, Re MC. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008, 80:1507-1514. 10.1002/jmv.21266, 18649336.
50. Gibellini D, Vitone F, Schiavone P, Ponti C, La Placa M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood monuclear cells by SYBR green real-time PCR technique. J Clin Virol 2004, 29:282-289. 10.1016/S1386-6532(03)00169-0, 15018857.
51. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof of concept study. Lancet 2005, 366:549-555. 10.1016/S0140-6736(05)67098-5, 1894952, 16099290.
52. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002, 76:10942-10500. 10.1128/JVI.76.21.10942-10950.2002, 136638, 12368337.
53. Kim DW. Real time quantitative PCR. Exp Mol Med 2001, 33:101-109.
54. De Gemmis P, Lapucci C, Bertelli M, Tognetto A, Fanin E, Vettor R, Pagano C, Pandolfo M, Fabbri A. A real-time PCR approach to evaluate adipogenic potential of amniotic fluid-derived human mesenchymal stem cells. Stem Cells Dev 2006, 15:719-726. 10.1089/scd.2006.15.719, 17105407.
55. Montaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based terapies. Cancer 2010, 116:2519-2530. 10.1002/cncr.25056, 20301117.
56. Chamberlain G, Fox J, Ashton B, Middleton J. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25:2739-2749. 10.1634/stemcells.2007-0197, 17656645.
57. Tavian M, Zheng B, Oberlin E, Crisan M, Sun B, Huard J, Peault B. The vascular wall as a source of stem cells. Ann N Y Acad Sci 2005, 1044:41-50. 10.1196/annals.1349.006, 15958696.
58. Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H, Weil J, Reichenspumer H, Kilic N, Ergun S. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 2006, 133:1543-1551. 10.1242/dev.02315, 16524930.
59. Passman JN, Dong XR, Wu SP, Maguire CT, Hogan KA, Bautch VL, Majesky MW. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci USA 2008, 105:9349-9354. 10.1073/pnas.0711382105, 2453724, 18591670.
60. Abedin M, Tintut Y, Demer LL. Mesenchymal stem cells and the artery wall. Circul Res 2004, 95:671-676.
61. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. J Acquir Immune Defic Syndr 2002, 30:471-477. 10.1097/00126334-200208150-00002, 12154337.
62. Moses A, Nelson J, Bagby G. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998, 91:1479-1495.
63. Chirmule N, Pahwa S. Envelope glycoproteins of human immunodeficiency virus type 1:profound influences on immune functions. Microbiol Rev 1996, 60:386-406. 239449, 8801439.
64. Re MC, Zauli G, Gibellini D, Furlini G, Ramazzotti E, Monari P, Ranieri S, Capitani S, La Placa M. Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS 1993, 7:1049-1055. 10.1097/00002030-199308000-00004, 7691085.
65. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992, 176:1099-1106. 10.1084/jem.176.4.1099, 2119378, 1402655.
66. Lawson VA, Silburn KA, Gorry PR, Paukovic G, Purcell DF, Greenway AL, McPhee DA. Apoptosis induced in synchronized human immunodeficiency virus type 1-infected primary peripheral blood mononuclear cells is detected after the peak of CD4+ T-lymphocyte loss and is dependent on the tropism of the gp120 envelope glycoprotein. Virology 2004, 327:70-82. 10.1016/j.virol.2004.06.012, 15327899.
67. Nacher M, Serrano S, Gonzalez A, Hernandez A, Marinoso ML, Vilella R, Hinarejos P, Diez A, Aubia J. Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS 2001, 15:2239-2243. 10.1097/00002030-200111230-00004, 11698696.
68. Adachi A, Koenig S, Gendelman HE, Daugherty D, Gattoni-Celli S, Fauci AS, Martin MA. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol 1987, 61:209-213. 255241, 3640832.
69. Nottet H, Janse I, De Graaf L, Bakker LJ, Visser MR, Verhoef J. Infection of epithelial cell line HEp-2 with human immunodeficiency virus type 1 is CD4 dependent. J Med Virol 1993, 40:39-43. 10.1002/jmv.1890400109, 8515246.
70. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-30343. (1998), 10.1074/jbc.273.46.30336, 9804796.
71. Grünewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010, 1804:567-580.
72. Chawla A, Lazar MA. Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 1994, 91:1786-1790. 10.1073/pnas.91.5.1786, 43248, 8127882.
73. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956. 10.1074/jbc.270.22.12953, 7768881.
74. MacDougal OA, Lane MD. Adipocyte differentiation. When precursors are also regulators. Curr Biol 1995, 5:618-621. 10.1016/S0960-9822(95)00125-4, 7552171.
75. Mandrup S, Lane MD. Regulating adipogenesis. J Biol Chem 1997, 272:5367-5370. 10.1074/jbc.272.9.5367, 9102400.
76. Wu Z, Xie Y, Bucher NL, Farmer SR. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev 1995, 9:2350-2363. 10.1101/gad.9.19.2350, 7557387.
77. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595. 10.1016/S1097-2765(00)80209-9, 10549290.
78. Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007, 23:1521-1530. 10.1089/aid.2007.0112, 18160010.
79. Cotter EJ, Mallon PW, Doran PP. Is PPARγ a prospective player in HIV-1 associated bone disease?. PPAR Res 2009, 2009:421376. 2659551, 19325916.
80. Popik W, Hesselgesser JE, Pitha PM. Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway. J Virol 1998, 72:6406-6413. 109793, 9658081.
81. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61. 10.1038/339058a0, 2469964.
82. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
83. Nikolova G, Strilic B, Lammert E. The vascular niche and its basement membrane. Trends Cell Biol 2007, 17:19-25. 10.1016/j.tcb.2006.11.005, 17129728.
84. Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti C, Quilchini R, Aubert L, Tamalet C, Juhan-Vague I, Gastaut JA. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992, 5:127-131.
85. Toulon P, Lamine M, Ledjev I, Guez T, Holleman ME, Sereni D, Sicard D. Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus. Thromb Haemost 1993, 70:730-735.
86. Dallasta LM, Pisarov LA, Esplen JE, Werley JV, Moses AV, Nelson JA, Achim CL. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999, 155:1915-1927. 10.1016/S0002-9440(10)65511-3, 1866950, 10595922.
87. Gibellini D, Zauli G, Re MC, Milani D, Furlini G, Caramelli E, Capitani S, La Placa M. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-beta 1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol 1994, 88:261-267. 10.1111/j.1365-2141.1994.tb05016.x, 7803268.
88. Hoffman FM, Chen P, Incardona F, Zidovetzki R, Hinton DR. HIV-1 tat protein induces the production of interleukin-8 by human brain-derived endothelial cells. J Neuroimmunol 1999, 94:28-39. 10.1016/S0165-5728(98)00198-2, 10376933.
89. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005, 333:1107-1115. 10.1016/j.bbrc.2005.05.198, 15979050.
90. Clouse KA, Cosentino LM, Weih KA, Pyle SW, Robbins PB, Hochstein HD, Natarajan V, Farrar WL. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991, 147:2892-2901.
91. El-Sadr WM, Mullin C, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005, 6:114-121. 10.1111/j.1468-1293.2005.00273.x, 15807717.
92. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008, 199:79-86. 10.1016/j.atherosclerosis.2007.10.018, 2518204, 18054941.
93. Qiao JH, Mertens RB, Fishbein MC, Geller SA. Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: morphologic evidence of enchondral ossification. Hum Pathol 2003, 34:402-407. 10.1053/hupa.2003.72, 12733123.
94. Tang T, Boyle JR, Dixon AK, Varty K. Inflammatory abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005, 29:353-362.